Anti-angiogenic treatment of gastrointestinal malignancies

J. Stuart Salmon, Albert Lockhart, Jordan Berlin

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

The scientific rationale to block angiogenesis as a treatment strategy for human cancer has been developed over the last 30 years, but is only now entering the clinical arena. Preclinical studies have demonstrated the importance of the vascular endothelial growth factor (VEGF) pathways in both physiologic and pathologic angiogenesis, and have led to the development of approaches to block its role in tumor angiogenesis. Bevacizumab is an antibody to VEGF and has been shown to prolong survival when given with chemotherapy in the treatment of metastatic colorectal cancer (CRC). Although this is the first anti-angiogenic treatment to be approved for the treatment of human epithelial malignancy, a number of other approaches currently are in development. Soluble chimeric receptors to sequester serum VEGF and monoclonal antibodies against VEGF receptors have both shown considerable promise in the laboratory and are being brought into clinical investigation. A number of small-molecule tyrosine kinase inhibitors that have activity against VEGF receptors also are in clinical trials. Although these novel treatments are being pioneered in CRC, anti-angiogenic approaches also are being tested in the treatment of other gastrointestinal malignancies. Anti-VEGF therapy has shown promise in such traditionally resistant tumors as pancreatic cancer and hepatocellular carcinoma. This review will examine the preclinical foundation and then focus on the clinical studies of anti-VEGF therapy in gastrointestinal cancers.

Original languageEnglish (US)
Pages (from-to)712-726
Number of pages15
JournalCancer Investigation
Volume23
Issue number8
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Neoplasms
Vascular Endothelial Growth Factor Receptor
Therapeutics
Colorectal Neoplasms
Physiologic Neovascularization
Pathologic Neovascularization
Gastrointestinal Neoplasms
Pancreatic Neoplasms
Protein-Tyrosine Kinases
Hepatocellular Carcinoma
Monoclonal Antibodies
Clinical Trials
Drug Therapy
Survival
Antibodies
Serum

Keywords

  • Angiogenesis
  • Anti-VEGF Therapy
  • Gastrointestinal Malignancies
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anti-angiogenic treatment of gastrointestinal malignancies. / Salmon, J. Stuart; Lockhart, Albert; Berlin, Jordan.

In: Cancer Investigation, Vol. 23, No. 8, 01.11.2005, p. 712-726.

Research output: Contribution to journalReview article

Salmon, J. Stuart ; Lockhart, Albert ; Berlin, Jordan. / Anti-angiogenic treatment of gastrointestinal malignancies. In: Cancer Investigation. 2005 ; Vol. 23, No. 8. pp. 712-726.
@article{89b1c8848db94b02a18ad1ef2dfe2b6e,
title = "Anti-angiogenic treatment of gastrointestinal malignancies",
abstract = "The scientific rationale to block angiogenesis as a treatment strategy for human cancer has been developed over the last 30 years, but is only now entering the clinical arena. Preclinical studies have demonstrated the importance of the vascular endothelial growth factor (VEGF) pathways in both physiologic and pathologic angiogenesis, and have led to the development of approaches to block its role in tumor angiogenesis. Bevacizumab is an antibody to VEGF and has been shown to prolong survival when given with chemotherapy in the treatment of metastatic colorectal cancer (CRC). Although this is the first anti-angiogenic treatment to be approved for the treatment of human epithelial malignancy, a number of other approaches currently are in development. Soluble chimeric receptors to sequester serum VEGF and monoclonal antibodies against VEGF receptors have both shown considerable promise in the laboratory and are being brought into clinical investigation. A number of small-molecule tyrosine kinase inhibitors that have activity against VEGF receptors also are in clinical trials. Although these novel treatments are being pioneered in CRC, anti-angiogenic approaches also are being tested in the treatment of other gastrointestinal malignancies. Anti-VEGF therapy has shown promise in such traditionally resistant tumors as pancreatic cancer and hepatocellular carcinoma. This review will examine the preclinical foundation and then focus on the clinical studies of anti-VEGF therapy in gastrointestinal cancers.",
keywords = "Angiogenesis, Anti-VEGF Therapy, Gastrointestinal Malignancies, VEGF",
author = "Salmon, {J. Stuart} and Albert Lockhart and Jordan Berlin",
year = "2005",
month = "11",
day = "1",
doi = "10.1080/07357900500360024",
language = "English (US)",
volume = "23",
pages = "712--726",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Anti-angiogenic treatment of gastrointestinal malignancies

AU - Salmon, J. Stuart

AU - Lockhart, Albert

AU - Berlin, Jordan

PY - 2005/11/1

Y1 - 2005/11/1

N2 - The scientific rationale to block angiogenesis as a treatment strategy for human cancer has been developed over the last 30 years, but is only now entering the clinical arena. Preclinical studies have demonstrated the importance of the vascular endothelial growth factor (VEGF) pathways in both physiologic and pathologic angiogenesis, and have led to the development of approaches to block its role in tumor angiogenesis. Bevacizumab is an antibody to VEGF and has been shown to prolong survival when given with chemotherapy in the treatment of metastatic colorectal cancer (CRC). Although this is the first anti-angiogenic treatment to be approved for the treatment of human epithelial malignancy, a number of other approaches currently are in development. Soluble chimeric receptors to sequester serum VEGF and monoclonal antibodies against VEGF receptors have both shown considerable promise in the laboratory and are being brought into clinical investigation. A number of small-molecule tyrosine kinase inhibitors that have activity against VEGF receptors also are in clinical trials. Although these novel treatments are being pioneered in CRC, anti-angiogenic approaches also are being tested in the treatment of other gastrointestinal malignancies. Anti-VEGF therapy has shown promise in such traditionally resistant tumors as pancreatic cancer and hepatocellular carcinoma. This review will examine the preclinical foundation and then focus on the clinical studies of anti-VEGF therapy in gastrointestinal cancers.

AB - The scientific rationale to block angiogenesis as a treatment strategy for human cancer has been developed over the last 30 years, but is only now entering the clinical arena. Preclinical studies have demonstrated the importance of the vascular endothelial growth factor (VEGF) pathways in both physiologic and pathologic angiogenesis, and have led to the development of approaches to block its role in tumor angiogenesis. Bevacizumab is an antibody to VEGF and has been shown to prolong survival when given with chemotherapy in the treatment of metastatic colorectal cancer (CRC). Although this is the first anti-angiogenic treatment to be approved for the treatment of human epithelial malignancy, a number of other approaches currently are in development. Soluble chimeric receptors to sequester serum VEGF and monoclonal antibodies against VEGF receptors have both shown considerable promise in the laboratory and are being brought into clinical investigation. A number of small-molecule tyrosine kinase inhibitors that have activity against VEGF receptors also are in clinical trials. Although these novel treatments are being pioneered in CRC, anti-angiogenic approaches also are being tested in the treatment of other gastrointestinal malignancies. Anti-VEGF therapy has shown promise in such traditionally resistant tumors as pancreatic cancer and hepatocellular carcinoma. This review will examine the preclinical foundation and then focus on the clinical studies of anti-VEGF therapy in gastrointestinal cancers.

KW - Angiogenesis

KW - Anti-VEGF Therapy

KW - Gastrointestinal Malignancies

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=29944445729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944445729&partnerID=8YFLogxK

U2 - 10.1080/07357900500360024

DO - 10.1080/07357900500360024

M3 - Review article

VL - 23

SP - 712

EP - 726

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 8

ER -